Neurological Disorder Drugs Global Market Report 2025

Description

Neurological disorder drugs are medications used to treat conditions affecting the nervous system, including the brain, spinal cord, and peripheral nerves. These drugs aim to manage symptoms, slow disease progression, and improve the quality of life for individuals affected by these disorders.

The main drug classes for neurological disorders include cholinesterase inhibitors, N-Methyl-D-Aspartate (NMDA) receptor antagonists, antiepileptics, antipsychotics, antidepressants, and others. Cholinesterase inhibitors, for example, prevent the breakdown of acetylcholine, a neurotransmitter crucial for memory and cognitive function. These medications can be used for various conditions such as epilepsy, Alzheimer's disease, Parkinson's disease, multiple sclerosis, cerebrovascular disease, and others. They can be administered orally, parenterally, or by other routes. Distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, and others, with end users being hospitals, specialty clinics, home care settings, and more.

The neurological disorder drugs market research report is one of a series of new reports from The Business Research Company that provides neurological disorder drugs market statistics, including neurological disorder drugs industry global market size, regional shares, competitors with a neurological disorder drugs market share, detailed neurological disorder drugs market segments, market trends and opportunities, and any further data you may need to thrive in the neurological disorder drugs industry. This neurological disorder drugs market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The neurological disorder drugs market size has grown strongly in recent years. It will grow from $84.6 billion in 2024 to $90.09 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to increasing animal testing and obtaining promising results, an increase in therapeutic treatments, the growth of neurological problems, government initiatives, and a growth in healthcare expenditure.

The neurological disorder drugs market size is expected to see strong growth in the next few years. It will grow to $114.65 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to expanding therapeutic options and personalized therapies, a growing focus on disease-modifying treatments, the expanding use of digital biomarkers, and the increasing prevalence of neurological diseases. Major trends in the forecast period include advancements in drug design, advancements in neuroimaging, advancements in genetic research, collaborations and licensing agreements, and the emergence of regenerative medicine.

The rising incidence of neurological diseases is expected to drive the growth of the neurological disorder drugs market in the coming years. Neurological disorders are conditions that affect the brain, spinal cord, and nerves, caused by structural, biochemical, or electrical disruptions, leading to various symptoms. The increase in these diseases is mainly attributed to an aging global population and heightened exposure to environmental, metabolic, and lifestyle risk factors. Drugs for neurological disorders are crucial in managing these complex conditions, providing symptom relief, slowing disease progression, and improving long-term patient outcomes. For example, in September 2024, the Australian Institute of Health and Welfare, a government agency based in Australia, projected that the number of individuals living with dementia in the country will more than double from approximately 411,100 in 2023 to 849,300 by 2058, with an estimated 315,500 men and 533,800 women affected. Therefore, the growing prevalence of neurological diseases is fueling the expansion of the neurological disorder drugs market.

Major companies in the neurological disorder drugs market are focusing on developing innovative Ocrelizumab drug therapies to enhance treatment efficacy, improve patient outcomes, and expand therapeutic options for multiple sclerosis patients. Ocrelizumab is a humanized monoclonal antibody used to treat multiple sclerosis (MS), a neurological disorder. For instance, in February 2024, Roche Holding AG, a Swiss pharmaceutical company, launched Ocrevus (Ocrelizumab) in India as a new disease-modifying therapy (DMT) for multiple sclerosis. Ocrevus is the first and only approved DMT for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS), backed by over ten years of clinical and real-world data. This monoclonal antibody targets CD20-positive B cells, believed to play a role in the autoimmune attack on the central nervous system in MS. Ocrevus treats both RRMS and PPMS, making it the first drug approved for both forms of the disease. It is administered intravenously every six months and has shown efficacy in reducing disease activity and disability progression in clinical trials.

In October 2022, Pfizer Inc., a US-based pharmaceutical company, acquired Biohaven Pharmaceuticals for $11.6 billion. This acquisition aims to bolster Pfizer's innovative internal medicine pipeline and global reach in migraine treatments by acquiring Biohaven's breakthrough calcitonin gene-related peptide portfolio, including the approved NURTEC ODT and pipeline assets such as Zavegepant. Pfizer plans to deliver these innovative therapies to over one billion people worldwide affected by migraines. Biohaven Pharmaceutical is a US-based clinical-stage biopharmaceutical company that offers a range of neurological and neuropsychiatric disorder drugs.

Major companies operating in the neurological disorder drugs market are F. Hoffmann-La Roche Ltd, Bayer AG, Sanofi S.A, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company Pvt Ltd, Amgen Inc, Boehringer Ingelheim GmbH, Novo Nordisk A/S, Merck KGaA, Teva Pharmaceutical Industries Ltd, Otsuka America Pharmaceutical Inc, Biogen Inc, Bausch Health Companies Inc, Alexion Pharmaceuticals Inc., UCB S.A., Eisai Co Ltd, Cipla Inc, BioMarin Pharmaceutical Inc., Biocon Ltd, Acorda Therapeutics Inc.

North America was the largest region in the neurological disorder drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurological disorder drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the neurological disorder drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neurological disorder drugs market consists of sales of antiepileptic drugs, dopaminergic agents, cholinesterase inhibitors, immunomodulatory drugs, and antipsychotic drugs. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neurological Disorder Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neurological disorder drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neurological disorder drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The neurological disorder drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Drug Class: Cholinesterase Inhibitors; N-Methyl-D-Aspartate (NMDA) Receptor Antagonists; Antiepileptic; Antipsychotic And Antidepressant; Other Drugs Classes
2) By Indication: Epilepsy; Alzheimer's Disease; Parkinson's Disease; Multiple Sclerosis; Cerebrovascular Disease; Other Indications
3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
5) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End Users
Subsegtments:
1) By Cholinesterase Inhibitors: Donepezil; Rivastigmine; Galantamine
2) By N-Methyl-D-Aspartate (NMDA) Receptor Antagonists: Memantine; Other NMDA Receptor Antagonists
3) By Antiepileptic: Sodium Channel Blockers; GABA Enhancers; Glutamate Modulators; Other Antiepileptics
4) By Antipsychotic and Antidepressant: Risperidone; Olanzapine; SSRIs; SNRIs; Tricyclic
5) By Other Drug Classes: Dopaminergic Drugs; Alpha-2 Agonists; Immunomodulators; Other Neurological Disorder Medications
Companies Mentioned: F. Hoffmann-La Roche Ltd; Bayer AG; Sanofi S.A; AstraZeneca PLC; Abbott Laboratories
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r30783

1. Executive Summary

2. Neurological Disorder Drugs Market Characteristics

3. Neurological Disorder Drugs Market Trends And Strategies

4. Neurological Disorder Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Neurological Disorder Drugs Growth Analysis And Strategic Analysis Framework

5.1. Global Neurological Disorder Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Neurological Disorder Drugs Market Growth Rate Analysis
5.4. Global Neurological Disorder Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Neurological Disorder Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Neurological Disorder Drugs Total Addressable Market (TAM)

6. Neurological Disorder Drugs Market Segmentation

6.1. Global Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cholinesterase Inhibitors
N-Methyl-D-Aspartate (NMDA) Receptor Antagonists
Antiepileptic
Antipsychotic And Antidepressant
Other Drugs Classes
6.2. Global Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Epilepsy
Alzheimer's Disease
Parkinson's Disease
Multiple Sclerosis
Cerebrovascular Disease
Other Indications
6.3. Global Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Parenteral
Other Routes Of Administration
6.4. Global Neurological Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Other Distribution Channels
6.5. Global Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
Homecare
Other End Users
6.6. Global Neurological Disorder Drugs Market, Sub-Segmentation Of Cholinesterase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Donepezil
Rivastigmine
Galantamine
6.7. Global Neurological Disorder Drugs Market, Sub-Segmentation Of N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Memantine
Other NMDA Receptor Antagonists
6.8. Global Neurological Disorder Drugs Market, Sub-Segmentation Of Antiepileptic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Sodium Channel Blockers
GABA Enhancers
Glutamate Modulators
Other Antiepileptics
6.9. Global Neurological Disorder Drugs Market, Sub-Segmentation Of Antipsychotic and Antidepressant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Risperidone
Olanzapine
SSRIs
SNRIs
Tricyclic
6.10. Global Neurological Disorder Drugs Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Dopaminergic Drugs
Alpha-2 Agonists
Immunomodulators
Other Neurological Disorder Medications

7. Neurological Disorder Drugs Market Regional And Country Analysis

7.1. Global Neurological Disorder Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Neurological Disorder Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Neurological Disorder Drugs Market

8.1. Asia-Pacific Neurological Disorder Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Neurological Disorder Drugs Market

9.1. China Neurological Disorder Drugs Market Overview
9.2. China Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Neurological Disorder Drugs Market

10.1. India Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Neurological Disorder Drugs Market

11.1. Japan Neurological Disorder Drugs Market Overview
11.2. Japan Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Neurological Disorder Drugs Market

12.1. Australia Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Neurological Disorder Drugs Market

13.1. Indonesia Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Neurological Disorder Drugs Market

14.1. South Korea Neurological Disorder Drugs Market Overview
14.2. South Korea Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Neurological Disorder Drugs Market

15.1. Western Europe Neurological Disorder Drugs Market Overview
15.2. Western Europe Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Neurological Disorder Drugs Market

16.1. UK Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Neurological Disorder Drugs Market

17.1. Germany Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Neurological Disorder Drugs Market

18.1. France Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Neurological Disorder Drugs Market

19.1. Italy Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Neurological Disorder Drugs Market

20.1. Spain Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Neurological Disorder Drugs Market

21.1. Eastern Europe Neurological Disorder Drugs Market Overview
21.2. Eastern Europe Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Neurological Disorder Drugs Market

22.1. Russia Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Neurological Disorder Drugs Market

23.1. North America Neurological Disorder Drugs Market Overview
23.2. North America Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Neurological Disorder Drugs Market

24.1. USA Neurological Disorder Drugs Market Overview
24.2. USA Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Neurological Disorder Drugs Market

25.1. Canada Neurological Disorder Drugs Market Overview
25.2. Canada Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Neurological Disorder Drugs Market

26.1. South America Neurological Disorder Drugs Market Overview
26.2. South America Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Neurological Disorder Drugs Market

27.1. Brazil Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Neurological Disorder Drugs Market

28.1. Middle East Neurological Disorder Drugs Market Overview
28.2. Middle East Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Neurological Disorder Drugs Market

29.1. Africa Neurological Disorder Drugs Market Overview
29.2. Africa Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Neurological Disorder Drugs Market Competitive Landscape And Company Profiles

30.1. Neurological Disorder Drugs Market Competitive Landscape
30.2. Neurological Disorder Drugs Market Company Profiles
- 30.2.1. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis

31. Neurological Disorder Drugs Market Other Major And Innovative Companies

31.1. Novartis AG
31.2. GlaxoSmithKline plc
31.3. Takeda Pharmaceutical Company Limited
31.4. Eli Lilly and Company Pvt Ltd
31.5. Amgen Inc.
31.6. Boehringer Ingelheim GmbH
31.7. Novo Nordisk A/S
31.8. Merck KGaA
31.9. Teva Pharmaceutical Industries Ltd.
31.10. Otsuka America Pharmaceutical Inc.
31.11. Biogen Inc.
31.12. Bausch Health Companies Inc.
31.13. Alexion Pharmaceuticals Inc.
31.14. UCB S.A.
31.15. Eisai Co. Ltd.

32. Global Neurological Disorder Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Neurological Disorder Drugs Market

34. Recent Developments In The Neurological Disorder Drugs Market

35. Neurological Disorder Drugs Market High Potential Countries, Segments and Strategies

35.1 Neurological Disorder Drugs Market In 2029 - Countries Offering Most New Opportunities
35.2 Neurological Disorder Drugs Market In 2029 - Segments Offering Most New Opportunities
35.3 Neurological Disorder Drugs Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer